Dr. Collin Hovinga will lead two public-private partnerships at C-Path — the Rare Disease Cures Accelerator Data and Analytics Platform (RDCA-DAP®) and the Critical Path for Rare Neurodegenerative Diseases (CP-RND).Continue reading
Author Archive: Roxan Olivas
C-Path and Sturge-Weber Foundation Announce Data Sharing Agreement to Support Treatment Development for Sturge-Weber Syndrome
TUCSON, Ariz., October 20, 2022 — Critical Path Institute (C-Path) and the Sturge-Weber Foundation today announced a joint collaboration to incorporate patient data for Sturge-Weber syndrome (SWS) into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading
C-Path’s Ramona Walls Promoted to Executive Director of Data Science
TUCSON, Ariz., October 20, 2022 — Critical Path Institute (C-Path) has named Ramona L. Walls, Ph.D., as Executive Director of Data Science within C-Path’s Data Collaboration Center (DCC).Continue reading
C-Path’s Transplant Therapeutics Consortium Receives EMA Draft Qualification Opinion for iBox Scoring System
The draft EMA qualification opinion is available for public consultation until November 17, 2022
Secondary endpoint prognostic for allograft loss to catalyze development of novel therapies intended to improve long-term outcomes for kidney transplant recipientsContinue reading
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
Board names Dr. Daniel Jorgensen as Chief Executive OfficerContinue reading
C-Path’s European Nonprofit Appoints Managing Director and New Board Member to Expand Global Efforts
TUCSON, Ariz. and AMSTERDAM, September 20, 2022 — Critical Path Institute’s (C-Path) European nonprofit today announced the appointment of Cécile Ollivier M.S. as Managing Director – Europe and Robert Hemmings, M.S., to its Board of Directors.Continue reading
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases
TUCSON, Ariz., Sept. 14, 2022 — Critical Path Institute (C-Path) has announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA). The Agency announced the PPP today in a press release.Continue reading
C-Path’s Kristen Swingle Named President
Swingle joined C-Path in 2019 and was named interim president in 2021
TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path through growth and innovation, including the establishment of multiple national and global programs, a new European entity, a 50% staff increase, and a 90% increase in revenue.Continue reading
C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases
TUCSON, Ariz., Sept. 1, 2022 — Critical Path Institute (C-Path) today announced the launch of a pre-consortium collaboration focused on accelerating medical product development in lysosomal diseases, supported by a grant from the U.S. Food and Drug Administration (FDA).Continue reading